Spontaneous Gonadotrophin Pulsatility and Ovarian Morphology in Girls With Central Precocious Puberty Treated With Cyproterone Acetate

Stanhope, R; Pringle, P. J.; Adams, J.; Jeffcoate, S. L.; Brook, C. G. D.

doi:10.1111/j.1365-2265.1985.tb01115.x

Cited by 8 publications

(5 citation statements)

References 23 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the studies that have examined ovarian volume and uterine size in girls with sexual precocity, most have studied only a small number of subjects (5,7,(12)(13)(14)(15)(16) or have not quoted specific values (5,14). One of the larger studies to date, by Lyon et al (13) examined 13 subjects with precocious puberty, and found that all subjects had a uterine length above the upper limit of normal.…”

Section: Discussionmentioning

confidence: 99%

Pelvic ultrasound findings in different forms of sexual precocity

Griffin¹,

Cole

Duncan

et al. 1995

Acta Paediatrica

View full text Add to dashboard Cite

Recently produced reference curves for various ultrasound dimensions were used to retrospectively assess 67 pelvic ultrasound scans carried out at the initial presentation in girls with sexual precocity. At presentation the group with precocious puberty had significantly increased uterine lengths and ovarian volumes compared with the normal population, and a significantly increased fundal-cervical ratio. Ovarian volume was also significantly increased in therlarche and thelarche variant. The fundal-cervical ratio was significantly increased in thelarche variant. There was considerable overlap between individuals with sexual precocity and normal subjects. The ultrasound findings that best discriminated early or precocious puberty from other forms of sexual precocity were the presence of a midline endometrial echo, and a uterine length above the 97th centile for age. An entirely normal pelvic ultrasound at presentation did not rule out the possibility of precocious puberty.

show abstract

Section: Discussionmentioning

confidence: 99%

Pelvic ultrasound findings in different forms of sexual precocity

Griffin¹,

Cole

Duncan

et al. 1995

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…The choice between the therapeutic options in the treatment of central precocious puberty may be decided by the incidence and nature of side effects. Unlike cyproterone acetate (26), GnRH analogues are specific in their action and although preliminary evidence has not shown that they cause an improvement in height prognosis, they may still be the preferred treatment for children with central precocious puberty, especially if a depot preparation proves reliable and effective.…”

Section: Discussionmentioning

confidence: 99%

Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) Analogue

1988

Self Cite

View full text Add to dashboard Cite

We have treated 14 girls with central precocious puberty for a mean period of 2.3 years (range, 0.5-3.9) with intranasal (D-Ser6) GnRH analogue administered in a mean dose of 28 micrograms/kg/day (range, 15-56). With the onset of treatment there was an initial increase in sitting height compared to subischial leg length, but overall there was no significant change in height standard deviation score for bone age. In this respect our results were indistinguishable from untreated children with central precocious puberty. There was a decrease in physiological GH secretion, associated with decreased sex steroid secretion, which probably accounts for the growth deceleration which has been described during GnRH analogue therapy. The effect of this growth deceleration combined with slowing of the rate of epiphyseal maturation may explain the absence of alteration in height prognosis.

show abstract

“…MPA and CPA reverse or arrest the progression of secondary sex characterises but have little to no effect on hormonal suppression [117,118] and auxological outcome [4,119]. In addition, both agents have undesirable side effects [4,120].…”

Section: Treatment Optionsmentioning

confidence: 97%

Gonadotropin-Releasing Hormone Analogue Treatment for Precocious Puberty

Heger

Sippell

Partsch

2005

Endocrine Development

View full text Add to dashboard Cite

Central precocious puberty (CPP) is the premature onset of puberty due to a precocious activation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. This condition results in accelerated development of secondary sex characteristics, accelerated bone maturation, impaired final height with disproportioned body appearance and can have a disturbing impact on the psychosocial behavior of children suffering from CPP. It is therefore necessary to assess the hormonal status of children who show pubertal signs before the age 8 years in girls and 9 years in boys. The indication for treatment should be made after evaluating pubertal progression, progression of bone age maturation and final height prognosis, development of reproductive function, and psychosocial adjustment and well-being. This paper summarizes the experience of GnRH agonist treatment, which is momentarily the treatment of choice for central precocious puberty in children.

show abstract

Spontaneous Gonadotrophin Pulsatility and Ovarian Morphology in Girls With Central Precocious Puberty Treated With Cyproterone Acetate

Cited by 8 publications

References 23 publications

Pelvic ultrasound findings in different forms of sexual precocity

Pelvic ultrasound findings in different forms of sexual precocity

Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) Analogue

Gonadotropin-Releasing Hormone Analogue Treatment for Precocious Puberty

Contact Info

Product

Resources

About